The clinical relevance of percentage improvements on the PANSS score [3]

Neuropsychopharmacology

Volumn 32, Issue 11, 2007, Pages 2435-2436

  Fleischhacker, W Wolfgang ^a   Kemmler, Georg ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

BRIEF PSYCHIATRIC RATING SCALE; CLINICAL GLOBAL IMPRESSION SCALE; DISEASE COURSE; DISEASE SEVERITY; HUMAN; LETTER; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; SCHIZOPHRENIA; SCORING SYSTEM;

CLINICAL TRIALS AS TOPIC; HUMANS; MENTAL DISORDERS; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX;

EID: 35348887215     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1301391     Document Type: Letter

References (5)

1. Andreasen NC, Carpenter Jr WT, Kane JM, Lasser RA, Marder SR, Weinberger DR (2005). Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 162: 441-449.
2. EMEA (1998). http://www.emea.europa.eu/pdfs/human/ewp/055995en.pdf.
3. Leucht S, Engel RR (2006). The relative sensitivity of the Clinical Global Impressions Scale and the Brief Psychiatric Rating Scale in antipsychotic drug trials. Neuropsychopharmacology 31: 406-412.
4. Leucht S, Kane JM, Etschel E, Kissling W, Hamann J, Engel RR (2006). Linking the PANSS, BRPS, and CGI: clinical implications. Neuropsychopharmacology 31: 2318-2325.
5. Van Os J, Burns T, Cavallaro R, Leucht S, Peuskens J, Helldin L et al (2006). Standardized remission criteria in schizophrenia. Acta Psychiatr Scand 113: 91-95.